- Home
- AKBA vs HEAR Comparison
AKBA vs HEAR Comparison
Compare AKBA & HEAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- HEAR
- Stock Information
- Founded
- AKBA 2007
- HEAR 1975
- Country
- AKBA United States
- HEAR United States
- Employees
- AKBA N/A
- HEAR N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- HEAR Telecommunications Equipment
- Sector
- AKBA Health Care
- HEAR Telecommunications
- Exchange
- AKBA Nasdaq
- HEAR Nasdaq
- Market Cap
- AKBA 336.2M
- HEAR 325.2M
- IPO Year
- AKBA 2014
- HEAR N/A
- Fundamental
- Price
- AKBA $1.88
- HEAR $15.78
- Analyst Decision
- AKBA Strong Buy
- HEAR Strong Buy
- Analyst Count
- AKBA 2
- HEAR 6
- Target Price
- AKBA $5.75
- HEAR $22.67
- AVG Volume (30 Days)
- AKBA 2.4M
- HEAR 208.0K
- Earning Date
- AKBA 11-07-2024
- HEAR 11-07-2024
- Dividend Yield
- AKBA N/A
- HEAR N/A
- EPS Growth
- AKBA N/A
- HEAR N/A
- EPS
- AKBA N/A
- HEAR 0.24
- Revenue
- AKBA $169,879,000.00
- HEAR $326,227,000.00
- Revenue This Year
- AKBA N/A
- HEAR $50.18
- Revenue Next Year
- AKBA $6.13
- HEAR $13.19
- P/E Ratio
- AKBA N/A
- HEAR $67.05
- Revenue Growth
- AKBA N/A
- HEAR 25.72
- 52 Week Low
- AKBA $0.80
- HEAR $9.77
- 52 Week High
- AKBA $2.48
- HEAR $18.45
- Technical
- Relative Strength Index (RSI)
- AKBA 61.05
- HEAR 51.57
- Support Level
- AKBA $1.75
- HEAR $14.60
- Resistance Level
- AKBA $2.02
- HEAR $16.69
- Average True Range (ATR)
- AKBA 0.11
- HEAR 0.84
- MACD
- AKBA -0.02
- HEAR -0.10
- Stochastic Oscillator
- AKBA 60.00
- HEAR 44.19
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About HEAR Turtle Beach Corporation
Turtle Beach Corp specializes in gaming accessories, offering a diverse range including headsets, controllers, keyboards, mice, and simulation hardware. With nearly five decades of expertise, it's a innovator in audio technology, particularly dominant in console gaming headsets. Expanding beyond headsets, Turtle Beach now offers game controllers, flight and racing simulation accessories, and high-quality microphones. Operating globally, its products are available through numerous major retailers such as Amazon, Argos, Best Buy, GAME, GameStop, EB Games, Media Markt, Saturn, Target, and Walmart, with a significant revenue portion generated during the holiday season. The majority of its revenue stems from North America.